{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:19:39Z","timestamp":1773101979070,"version":"3.50.1"},"reference-count":69,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01AI139106"],"award-info":[{"award-number":["R01AI139106"]}]},{"name":"NIH","award":["P20GM103625"],"award-info":[{"award-number":["P20GM103625"]}]},{"name":"UAMS","award":["R01AI139106"],"award-info":[{"award-number":["R01AI139106"]}]},{"name":"UAMS","award":["P20GM103625"],"award-info":[{"award-number":["P20GM103625"]}]},{"name":"UAMS VCRI pioneer","award":["R01AI139106"],"award-info":[{"award-number":["R01AI139106"]}]},{"name":"UAMS VCRI pioneer","award":["P20GM103625"],"award-info":[{"award-number":["P20GM103625"]}]},{"name":"River Valley Ovarian Cancer Alliance Research","award":["R01AI139106"],"award-info":[{"award-number":["R01AI139106"]}]},{"name":"River Valley Ovarian Cancer Alliance Research","award":["P20GM103625"],"award-info":[{"award-number":["P20GM103625"]}]},{"name":"NIH National Institute of General Medical Sciences Centers of Biomedical Research Excellence","award":["R01AI139106"],"award-info":[{"award-number":["R01AI139106"]}]},{"name":"NIH National Institute of General Medical Sciences Centers of Biomedical Research Excellence","award":["P20GM103625"],"award-info":[{"award-number":["P20GM103625"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Myxoma virus (MYXV), a rabbit-specific poxvirus and non-pathogenic in humans and mice, is an excellent candidate oncolytic virus for cancer therapy. MYXV also has immunotherapeutic benefits. In ovarian cancer (OC), immunosuppressive tumor-associated macrophages (TAMs) are key to inhibiting antitumor immunity while hindering therapeutic benefit by chemotherapy and dendritic cell (DC) vaccine. Because MYXV favors binding\/entry of macrophages\/monocytes, we examined the therapeutic potential of MYXV against TAMs. We found previously that a replication-defective MYXV with targeted deletion of an essential gene, M062R, designated \u0394M062R MYXV, activated both the host DNA sensing pathway and the SAMD9 pathway. Treatment with \u0394M062R confers therapeutic benefit comparable to that of wild-type replicating MYXV in preclinical models. Here we found that \u0394M062R MYXV, when integrated with cisplatin and DC immunotherapy, further improved treatment benefit, likely through promoting tumor antigen-specific T cell function. Moreover, we also tested \u0394M062R MYXV in targeting human immunosuppressive TAMs from OC patient ascites in a co-culture system. We found that \u0394M062R treatment subverted the immunosuppressive properties of TAMs and elevated the avidity of cytokine production in tumor antigen-specific CD4+ T cells. Overall, \u0394M062R presents a promising immunotherapeutic platform as a beneficial adjuvant to chemotherapy and DC vaccine.<\/jats:p>","DOI":"10.3390\/v17081058","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T09:31:45Z","timestamp":1753781505000},"page":"1058","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-187X","authenticated-orcid":false,"given":"Martin J.","family":"Cannon","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-7972","authenticated-orcid":false,"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"v181","DOI":"10.1093\/annonc\/mdj978","article-title":"Challenges for chemotherapy in ovarian cancer","volume":"17","author":"Ozols","year":"2006","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.\/ESMO"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2021.02.007","article-title":"Targeting the tumour microenvironment in platinum-resistant ovarian cancer","volume":"77","author":"Cummings","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_4","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(10)62231-3","article-title":"Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995\u20132007 (the International Cancer Benchmarking Partnership): An analysis of population-based cancer registry data","volume":"377","author":"Coleman","year":"2011","journal-title":"Lancet"},{"key":"ref_7","first-page":"67","article-title":"Immunological parameters as a new lead in the diagnosis of ovarian cancer","volume":"7","author":"Baert","year":"2015","journal-title":"Facts Views Vis. ObGyn"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1111505","DOI":"10.1080\/2162402X.2015.1111505","article-title":"Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course","volume":"5","author":"Coosemans","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2018.01.014","article-title":"Tumor associated macrophages in gynecologic cancers","volume":"149","author":"Krishnan","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Blanc-Durand, F., Clemence Wei Xian, L., and Tan, D.S.P. (2023). Targeting the immune microenvironment for ovarian cancer therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1328651"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Goyne, H.E., and Cannon, M.J. (2013). Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00382"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1517\/14712598.2011.554812","article-title":"Dendritic cell vaccination against ovarian cancer--tipping the Treg\/TH17 balance to therapeutic advantage?","volume":"11","author":"Cannon","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rahman, M.M., and McFadden, G. (2020). Oncolytic Virotherapy with Myxoma Virus. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010171"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12704","DOI":"10.1128\/JVI.01483-07","article-title":"Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits","volume":"81","author":"Stanford","year":"2007","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tosic, V., Thomas, D.L., Kranz, D.M., Liu, J., McFadden, G., Shisler, J.L., MacNeill, A.L., and Roy, E.J. (2014). Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109801"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.omto.2021.07.014","article-title":"Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma","volume":"22","author":"Christie","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1016\/j.vaccine.2013.05.056","article-title":"Oncolytic myxoma virus: The path to clinic","volume":"1","author":"Chan","year":"2013","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Conrad, S.J., Raza, T., Peterson, E.A., Liem, J., Connor, R., Nounamo, B., Cannon, M., and Liu, J. (2022). Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes\/macrophages. PLoS Pathog., 18.","DOI":"10.1101\/2022.01.30.478420"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ccell.2022.08.001","article-title":"Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance","volume":"40","author":"Zheng","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omto.2017.08.002","article-title":"Myxoma virus optimizes cisplatin for the treatment of ovarian cancer in vitro and in a syngeneic murine dissemination model","volume":"6","author":"Nounamo","year":"2017","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/mt.2011.293","article-title":"Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer","volume":"20","author":"Wennier","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1158\/0008-5472.CAN-18-0447","article-title":"In vivo estimation of oncolytic virus populations within tumors","volume":"78","author":"Jung","year":"2018","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Sig Transduct. Target. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/s41467-020-18962-z","article-title":"Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients","volume":"11","author":"Block","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e007661","DOI":"10.1136\/jitc-2023-007661","article-title":"Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade","volume":"11","author":"Luo","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/JVI.02243-10","article-title":"M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells","volume":"85","author":"Liu","year":"2011","journal-title":"J. Virol."},{"key":"ref_28","first-page":"Unit 14A 1","article-title":"Myxoma virus: Propagation, purification, quantification, and storage","volume":"14","author":"Smallwood","year":"2010","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.2353\/ajpath.2009.090328","article-title":"Type I Interferon Modulates Monocyte Recruitment and Maturation in Chronic Inflammation","volume":"175","author":"Lee","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.4049\/jimmunol.180.7.5101","article-title":"A Novel Type I IFN-Producing Cell Subset in Murine Lupus1","volume":"180","author":"Lee","year":"2008","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1084\/jem.20080462","article-title":"TLR7-dependent and Fc\u03b3R-independent production of type I interferon in experimental mouse lupus","volume":"205","author":"Lee","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.4049\/jimmunol.1001328","article-title":"Interleukin-1 alpha modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil","volume":"186","author":"Lee","year":"2011","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00262-013-1391-0","article-title":"Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen","volume":"62","author":"Cannon","year":"2013","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CJI.0000000000000030","article-title":"Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase","volume":"37","author":"Goyne","year":"2014","journal-title":"J. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/vaccines3020448","article-title":"Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages","volume":"3","author":"Cannon","year":"2015","journal-title":"Vaccines"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ijc.11617","article-title":"Expression of sperm protein 17 (Sp17) in ovarian cancer","volume":"108","author":"Straughn","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jim.2007.01.010","article-title":"A NOD\/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17","volume":"321","author":"Grizzi","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1007\/s12032-011-0137-0","article-title":"Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells","volume":"29","author":"Song","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/vaccines3040875","article-title":"A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes","volume":"3","author":"Xiang","year":"2015","journal-title":"Vaccines"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11523-013-0293-6","article-title":"Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma","volume":"9","author":"Song","year":"2014","journal-title":"Target. Oncol."},{"key":"ref_41","first-page":"6527306","article-title":"Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients","volume":"2017","author":"Anderson","year":"2017","journal-title":"Adv. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Chiriva-Internati, M., Yu, Y., Mirandola, L., Jenkins, M.R., Chapman, C., Cannon, M., Cobos, E., and Kast, W.M. (2010). Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010471"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Raza, T., Perterson, E., Liem, J., and Liu, J. (2024). Antagonizing the SAMD9 pathway is key to myxoma virus host shut-off and immune evasion. bioRxiv, 2024.02.01.578447.","DOI":"10.1101\/2024.02.01.578447"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.7150\/jca.87881","article-title":"Impact of Treatment Delay on the Prognosis of Patients with Ovarian Cancer: A Population-based Study Using the Surveillance, Epidemiology, and End Results Database","volume":"15","author":"Zhao","year":"2024","journal-title":"J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2011.10.003","article-title":"Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer","volume":"124","author":"Nagel","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101217","DOI":"10.1016\/j.tranon.2021.101217","article-title":"Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer","volume":"14","author":"Hopkins","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1128\/JVI.03488-12","article-title":"Myxoma and vaccinia viruses bind differentially to human leukocytes","volume":"87","author":"Chan","year":"2013","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1158\/0008-5472.CAN-05-1201","article-title":"Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas","volume":"65","author":"Lun","year":"2005","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Rahman, M.M., and McFadden, G. (2021). Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13215452"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/sj.mt.6300348","article-title":"Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo","volume":"16","author":"Stanford","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1128\/JVI.01408-06","article-title":"Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells","volume":"81","author":"Stanford","year":"2007","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1038\/mto.2015.13","article-title":"Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis","volume":"2","author":"Tong","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","article-title":"Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus","volume":"18","author":"Bartee","year":"2012","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clml.2015.12.005","article-title":"Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells","volume":"16","author":"Bartee","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.leukres.2012.01.020","article-title":"Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro","volume":"36","author":"Madlambayan","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Jazowiecka-Rakus, J., Pogoda-Mieszczak, K., Rahman, M.M., McFadden, G., and Sochanik, A. (2024). Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood-Brain Barrier and Treat Murine Glioma. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252011225"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-011-1045-z","article-title":"Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors","volume":"60","author":"Thomas","year":"2011","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/neuonc\/not035","article-title":"Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin","volume":"15","author":"Zemp","year":"2013","journal-title":"Neuro-oncology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.virol.2017.01.004","article-title":"An interaction domain in human SAMD9 is essential for myxoma virus host-range determinant M062 antagonism of host anti-viral function","volume":"503","author":"Nounamo","year":"2017","journal-title":"Virology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/JVI.02262-14","article-title":"SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.micinf.2010.08.012","article-title":"The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics","volume":"12","author":"Liu","year":"2010","journal-title":"Microbes Infect.\/Inst. Pasteur"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lee, K.-W., Yam, J.W.P., and Mao, X. (2023). Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells, 12.","DOI":"10.3390\/cells12172147"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhang, X.-W., Wu, Y.-S., Xu, T.-M., and Cui, M.-H. (2023). CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. Biomolecules, 13.","DOI":"10.3390\/biom13030465"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3857\/roj.2019.00640","article-title":"The emerging role of myeloid-derived suppressor cells in radiotherapy","volume":"38","author":"Kang","year":"2020","journal-title":"Radiat. Oncol. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.28205","article-title":"Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma","volume":"13","author":"Villa","year":"2022","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jcyt.2015.12.007","article-title":"Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells","volume":"18","author":"Villa","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Villa, N.Y., Rahman, M.M., McFadden, G., and Cogle, C.R. (2016). Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses, 8.","DOI":"10.3390\/v8030085"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/8\/1058\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:46Z","timestamp":1760033866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/8\/1058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":69,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["v17081058"],"URL":"https:\/\/doi.org\/10.3390\/v17081058","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}